Kintara Therapeutics, Inc.

This phase 2 trial tested a drug called VAL-083 combined with standard radiation in 29 people with newly diagnosed glioblastoma, a fast-growing brain cancer. The study focused on patients whose tumors have a specific genetic marker (unmethylated MGMT) that makes them resistant to…